Reviewer's report

Title: Multicenter Comparison of PEG-IFN 2a or 2b Plus Ribavirin for Treatment-naive HCV Patient in Korean Population

Version: 2 Date: 5 March 2013

Reviewer: Eckart Schott

Reviewer's report:

I feel that the authors have addressed most of the reviewers' concerns adequately. There remain a few concerns that should be addressed before the article can be published:

• Page 14, 2nd paragraph: it is not clear, which value relates to which treatment arm or to RVR/no-RVR, respectively.
• Page 22, 1st paragraph: No further clinical trials will be conducting with dual treatment of interferon/ribavirin. The sentence should be deleted.
• The statistics in table 4 still need to be clarified: The authors explain in their rebuttal letter that they compared the frequency of grade 1-2 with the frequency of grade 3 AEs (p=0.23). However, the legend to the table states that p=0.23 stands for the comparison of IFNa2a vs. IFNa2b. Which is correct? If it is for IFNa2a vs IFNa2b, does the p apply to the comparison of grade 1/2 side effects or of grade 3 side effects?

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received lecture fees, travel support and compensation for advisory boards from Roche and MSD.